• AHA
  • ESC
  • ASCO
  • ACC
  • RSNA
  • ISC
  • SABCS
  • AACR
  • APA
  • Archives
株式会社ヘスコインターナショナルは、法令を遵守し本サイトをご利用いただく皆様の個人情報の取り扱いに細心の注意を払っております。


Imatinib is superior to interferon-alfa and cytarabine as first-line therapy for newly diagnosed chronic myeloid leukemia

Imatinib is superior to the current standard of interferon-alfa and cytarabine for the first-line treatment of newly diagnosed chronic-phase chronic myeloid leukemia, according to trial results presented during the plenary session of the Annual Meeting of the American Society of Hematology. The IRIS trial (International Randomized Interferon versus STI571 study) is the largest clinical trial to compare the two chemotherapy treatments.

"Results of our study showed that the use of imatinib resulted in a significantly higher response rate and a longer period of time before the disease progressed," said Richard Larson, M.D., study presenter. "This is very encouraging news for patients and should be viewed as a positive step forward in the treatment of chronic myeloid leukemia."

Imatinib therapy improved a number of clinical outcomes: complete hematologic response (estimated at 97 percent versus 69 percent with combination chemotherapy), major cytogenetic response (87 percent versus 35 percent), complete cytogenetic response (76 percent versus 14 percent) and progression-free survival (time from diagnosis to disease progression or death, 92 percent versus 73 percent).

The 1,106 study participants were randomized to imatinib 400 mg daily by mouth or to combination interferon-alfa and cytarabine by injection. The target dose for interferon was 5 MU/m2/day subcutaneously, whereas target dose for cytarabine was 20mg/m2 subcutaneously for 10 days every month. The most recent data were analyzed 18 months after the last patients were enrolled in the phase III trial.



DOLについて - 利用規約 -  会員規約 -  著作権 - サイトポリシー - 免責条項 - お問い合わせ
Copyright 2000-2025 by HESCO International, Ltd.